Dr. Jonathan Scott Leventhal, MD

Dr. Leventhal practices at Yale Medicine in New Haven, Connecticut.

Dr. Leventhal's NPI, 1629338728, was assigned on May 22, 2012. Dr. Leventhal graduated from New York University School of Medicine in 2012. Dr. Leventhal holds Connecticut license 054840.

Dr. Leventhal's primary practice is Yale Medicine, at 50 Division St, New Haven, CT 06511 in South Central Ct County. The practice phone is (203) 785-2140.

Dr. Leventhal's primary practice is Yale Medicine in New Haven, Connecticut. Dr. Leventhal is also affiliated with Yale New Haven Hospital. The medical group on file is Yale Health. Dmand AI also links Dr. Leventhal to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Leventhal practices, 4 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Leventhal's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Leventhal is licensed in Connecticut.

CMS data shows 3,531 Medicare services from Dr. Leventhal across 9 procedure codes in 2024, for 873 Medicare patients. Medicare paid $124,833 for them.

CMS counts 873 Medicare patients who saw Dr. Leventhal in 2024. The largest group is 65 to 74, with 385 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Leventhal's median patient age at 71, with 53% women.

In 2024, Dr. Leventhal wrote 3,947 Medicare Part D claims for 932 patients. 82% of them were for generic drugs. CMS names the drug for 3,616 of them, across 43 drugs with 11 or more claims each, at $3,493,154 in total drug cost. In 2023, CMS named 3,251 claims across 46 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Leventhal for performance year 2024, reported as part of a group. Dr. Leventhal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Leventhal as offering telehealth. CMS counts 815 procedures of removal of skin lesions by Dr. Leventhal, more than 91% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links Dr. Leventhal to 1 clinical trial. 1 is still active or recruiting. Open Payments lists research payments to Dr. Leventhal that name 1 trial.

CMS Open Payments shows 32 general payments to Dr. Leventhal from 6 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 89% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $8,525. It also lists 6 research payments totaling $34,567 from 2021 to 2022, naming 1 clinical trial.

Dr. Leventhal graduated from New York University School of Medicine in 2012.